AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 262 min read$RVMD

Anders Jack sold $3.4M of RVMD

Anders Jack (Chief Financial Officer) sold 20,000 shares of Revolution Medicines, Inc. (RVMD) at an average of $168.33 ($167.34–$170.32, $3.37M total) across 4 trades on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Anders Jack
Published Jun 26, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:58 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$RVMD
Neutral
high confidence
Mentioned
$RVMD
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RVMDNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale amount and execution window, with explicit confirmation of a pre-arranged 10b5-1 plan.

02

Market read

This provides incremental sentiment data (insider selling) but no new fundamental information to drive repricing.

03

What to watch

Traders may over-weight insider sales; the key missing context is whether there were concurrent buys by other insiders or any new RVMD-specific catalysts around the same period.

Relevance 5/10Novelty 3/10Timing: filed 2026-06-26, covering sales executed 2026-06-24

Background

The article is an SEC Form 4 insider transaction disclosure for Revolution Medicines, Inc. (RVMD).

Company-level read

Ticker impact

$RVMDNeutralHigh confidence
Context

Revolution Medicines CFO Anders Jack sold about 20,000 shares in open-market trades totaling $3.37M under a 10b5-1 plan.

Expected impact

Limited near-term impact; any effect is likely sentiment-only and outweighed by broader fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and it does not include new company guidance, trial results, or regulatory/contract developments.

Market effects

Sector

Minimal; insider-sale Form 4s typically do not reset biotech sector expectations without accompanying fundamental news.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so the market reaction should be muted.

Key entities

  • issuer
    Revolution Medicines, Inc.

    Biopharma company whose CFO insider sale is disclosed on Form 4.

  • insider
    Anders Jack

    Chief Financial Officer who executed the reported open-market sales.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RVMD insider trading history →

Related articles

SEP 4
$RVMDHighAI 8/10

Michael Osterholm Says He's Staying Four More Years as Public Health's Systems Buckle — BigGo Finance

Revolution Medicines' FDA-approved cancer drug, divarasib and razabi, targets RAS protein, previously deemed undruggable. CEO Mark Goldsmith bet the company on this target, leading to a successful Phase 3 trial. Michael Osterholm, 73, delayed retirement to address public health challenges, launching the Vaccine Integrity Project. David Baker, Nobel laureate, focuses on designing novel proteins and mentoring scientists.

finance.biggo.com2 min
SEP 3
$RVMDHighAI 9/10

Daraxonrasib shrinks tumours in one-third of lung cancer patients

Revolution Medicines Inc. (RVMD) reported that its experimental drug daraxonrasib shrank tumors in 33% of advanced lung cancer patients in a Phase 1/2 trial, with symptom improvements. The study, published in the New England Journal of Medicine, involved 136 patients with RAS gene mutations. The drug targets multiple RAS mutations and showed a median response duration of 11.5 months. Side effects were common, with rash, diarrhea, and nausea affecting many patients. The company is now conducting

mugglehead.com2 min
SEP 3
$RVMDMedAI 8/10

RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer

Revolution Medicines (RVMD) presented updated Phase 1/2 trial data for Rasonque in non-small cell lung cancer (NSCLC), showing a 42% overall response rate, 8.3-month median progression-free survival, and 16-month median overall survival. Truist Securities noted the results support RVMD's Phase 3 lung cancer study. Rasonque was recently FDA-approved for pancreatic cancer, with Phase 3 results expected in December 2027 for NSCLC.

biospace.com2 min
SEP 3
$RVMDMedAI 8/10

NEJM publishes daraxonrasib NSCLC data supporting Phase III program

Revolution Medicines (RVMD) published Phase I/II data in NEJM showing daraxonrasib's antitumor activity in RAS-mutant NSCLC. The study reported a 42% response rate and 8.3-month median progression-free survival. The company is advancing the drug in a Phase III trial. Daraxonrasib was recently approved for pancreatic cancer, marking the company's first commercial product.

allsci.com2 min
SEP 2
$RVMDMedAI 9/10

RVMD Shares React as Phase 1/2 RASONQUE Data Published in NEJM

Revolution Medicines (RVMD) announced the publication of Phase 1/2 trial results for RASONQUE in the New England Journal of Medicine. The data showed promising efficacy and safety in treating advanced RAS mutant NSCLC. The company has a market cap of $44.85 billion and is currently unprofitable, with a high Price-to-Sales ratio of 70.5x. Insider activity shows significant selling, while guru ownership trends are mixed.

gurufocus.com3 min